CRISPR Therapeutics AG

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

CRISPR Therapeutics AG reported 3.51M in revenue for fiscal year 2025, up from 37.31M in the previous year.

CRISPR Therapeutics AG reported 1.46M in revenue for the most recent quarter, an increase of 68.55% year over year.

CRISPR Therapeutics AG posted -581.60M in net income for fiscal year 2025.

CRISPR Therapeutics AG reported -122.93M in net income for the latest quarter。

CRISPR Therapeutics AG's operating income was -568.32M for fiscal year 2025.

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.